The authors showed that antibodies targeting PD‐L1 (checkpoint inhibitors), to promote anti‐tumour immunity, were more effective in mice lacking YTHDF1 leading to the suggestion that this methylase could be a therapeutic target alongside checkpoint inhibitors [101]. This evidence concerns the gene YTHDF1 and neoplasm.